May 15, 2013
The global epidemic crossed a significant threshold when, for the first time, according to new statistics, half of those living with HIV were women.
The U.S. National Institutes of Health released a press statement titled "Nevirapine Sustains Advantage Over AZT During Breastfeeding Period." The press release goes on to describe how infants who receive a single dose of the inexpensive drug nevirapine (Viramune) soon after birth -- and whose mothers took one dose of the same drug during labor -- were 41 percent less likely to acquire HIV at birth or during breastfeeding than infants in infant/mother pairs who were treated with a multi-dose regimen using AZT. Anthony Fauci states, "This landmark study could have far-reaching implications in resource-poor countries where breastfeeding and mother-to-child HIV transmission are both common."
Sister Mary Elizabeth Clark, a transgender nun and founder of the website AIDS Education Global Information System (AEGiS), receives an award at the event Honoring Our Heroes 2003 in Chicago.
Additional reporting was provided by Mathew Rodriguez, editorial project manager for TheBody.com and TheBodyPRO.com.Check out the other slide shows in the series:
For a more complete timeline in text only, check out A Timeline of Women Living With HIV: Past, Present and Future, by Terri Wilder.
The content on this page is free of advertiser influence and was produced by our editorial team. See our advertising policy.
More Slideshows Like This
HIV Tools You Can Use